The Experts below are selected from a list of 282 Experts worldwide ranked by ideXlab platform
F. B. Lammes - One of the best experts on this subject based on the ideXlab platform.
-
Disease Free Interval and recurrence pattern after the okabayashi variant of wertheim s radical hysterectomy for stage ib and iia cervical carcinoma
International Journal of Gynecological Cancer, 1996Co-Authors: Rahul A.k. Samlal, Jacobus Van Der Velden, B.w. Ketting, A. A. M. Hart, Gonzalez D Gonzalez, F Ten J W Kate, F. B. LammesAbstract:From January 1982 to December 1991 271 patients underwent radical hysterectomy according to the Okabayashi modification for cervical carcinoma stage IB and IIA. Intraoperative complications occurred in 3.3%. The urinary fistula rate was only 2.2%. The 5-year Disease-Free Interval (DFI) was 90%. In a univariate analysis tumor size 3 cm (n = 99), positive pelvic nodes (n = 53), adenocarcinoma (n = 58) and parametrial involvement (n = 36) were all associated with a significantly decreased DFI. Recurrence occurred in 27 patients (10%) of whom 22 died of Disease. In adenocarcinoma, DFI was poor when positive pelvic nodes were present. In squamous cell carcinoma however, DFI was not influenced by pelvic node status. In patients with squamous cell carcinoma the locoregional recurrence rate was 3.4% when pelvic nodes were negative, whereas in those with positive nodes it was 5.8%. These data show that the Okabayashi modification of Wertheim’s radical hysterectomy is a safe procedure resulting in very good locoregional tumor control, especially in patients with squamous cell cancer of the cervix.
-
Disease‐Free Interval and recurrence pattern after the Okabayashi variant of Wertheim’s radical hysterectomy for stage IB and IIA cervical carcinoma
International Journal of Gynecological Cancer, 1996Co-Authors: Rahul A.k. Samlal, Jacobus Van Der Velden, B.w. Ketting, D. González González, F.j.w. Ten Kate, A. A. M. Hart, F. B. LammesAbstract:From January 1982 to December 1991 271 patients underwent radical hysterectomy according to the Okabayashi modification for cervical carcinoma stage IB and IIA. Intraoperative complications occurred in 3.3%. The urinary fistula rate was only 2.2%. The 5-year Disease-Free Interval (DFI) was 90%. In a univariate analysis tumor size 3 cm (n = 99), positive pelvic nodes (n = 53), adenocarcinoma (n = 58) and parametrial involvement (n = 36) were all associated with a significantly decreased DFI. Recurrence occurred in 27 patients (10%) of whom 22 died of Disease. In adenocarcinoma, DFI was poor when positive pelvic nodes were present. In squamous cell carcinoma however, DFI was not influenced by pelvic node status. In patients with squamous cell carcinoma the locoregional recurrence rate was 3.4% when pelvic nodes were negative, whereas in those with positive nodes it was 5.8%. These data show that the Okabayashi modification of Wertheim’s radical hysterectomy is a safe procedure resulting in very good locoregional tumor control, especially in patients with squamous cell cancer of the cervix.
Alain Piché - One of the best experts on this subject based on the ideXlab platform.
-
The prosurvival activity of ascites against TRAIL is associated with a shorter Disease-Free Interval in patients with ovarian cancer
Journal of Ovarian Research, 2010Co-Authors: Denis Lane, Isabelle Matte, Claudine Rancourt, Alain PichéAbstract:Background The production of ascites is a common complication of ovarian cancer. Ascites constitute a unique tumor microenvironment that may affect Disease progression. In this context, we recently showed that ovarian cancer ascites may protect tumor cells from TRAIL-induced apoptosis. In this study, we sought to determine whether the prosurvival effect of ascites affects Disease-Free Intervals. Methods Peritoneal fluids were obtained from 54 women undergoing intra-abdominal surgery for suspected ovarian cancer (44 cancers and 10 benign Diseases). The ability of peritoneal fluids to protect from TRAIL was assessed in the ovarian cancer cell line CaOV3, and IC_50 were determined. The anti-apoptotic activity of 6 ascites against cisplatin, paclitaxel, doxorubicin, etoposide and vinorelbine was also assessed in CaOV3 cells, and the prosurvival activity of two ascites was assessed in 9 primary ovarian cancer cultures. Results Among the 54 peritoneal fluids tested, inhibition of TRAIL cytotoxicity was variable. Fluids originating from ovarian cancer were generally more protective than fluids from non-malignant Diseases. Most of the 44 ovarian cancer ascites increased TRAIL IC_50 and this inhibitory effect did not correlate strongly with the protein concentration in these ascites or the levels of serum CA125, a tumor antigen which is used in the clinic as a marker of tumor burden. The effect of ascites on cisplatin- and paclitaxel-induced cell death was assessed with 4 ascites having inhibitory effect on TRAIL-induced cell death and 2 that do not. The four ascites with prosurvival activity against TRAIL had some inhibitory on cisplatin and/or paclitaxel. Two ovarian cancer ascites, OVC346 and OVC509, also inhibited TRAIL cytotoxicity in 9 primary cultures of ovarian tumor and induced Akt activation in three of these primary cultures. Among a cohort of 35 patients with ascites, a threshold of TRAIL IC_50 with ascites/IC_50 without ascites > 2 was associated with shorter Disease-Free Interval. Conclusions The prosurvival activity of ascites against TRAIL is associated with shorter Disease-Free Interval, which may be explained, at least in part, by ascites-induced cisplatin/paclitaxel resistance. Our findings suggest that ascites may contain prosurvival factors that protect against TRAIL and chemotherapy and consequently affect Disease progression.
-
The prosurvival activity of ascites against TRAIL is associated with a shorter Disease-Free Interval in patients with ovarian cancer
Journal of ovarian research, 2010Co-Authors: Denis Lane, Isabelle Matte, Claudine Rancourt, Alain PichéAbstract:The production of ascites is a common complication of ovarian cancer. Ascites constitute a unique tumor microenvironment that may affect Disease progression. In this context, we recently showed that ovarian cancer ascites may protect tumor cells from TRAIL-induced apoptosis. In this study, we sought to determine whether the prosurvival effect of ascites affects Disease-Free Intervals. Peritoneal fluids were obtained from 54 women undergoing intra-abdominal surgery for suspected ovarian cancer (44 cancers and 10 benign Diseases). The ability of peritoneal fluids to protect from TRAIL was assessed in the ovarian cancer cell line CaOV3, and IC50 were determined. The anti-apoptotic activity of 6 ascites against cisplatin, paclitaxel, doxorubicin, etoposide and vinorelbine was also assessed in CaOV3 cells, and the prosurvival activity of two ascites was assessed in 9 primary ovarian cancer cultures. Among the 54 peritoneal fluids tested, inhibition of TRAIL cytotoxicity was variable. Fluids originating from ovarian cancer were generally more protective than fluids from non-malignant Diseases. Most of the 44 ovarian cancer ascites increased TRAIL IC50 and this inhibitory effect did not correlate strongly with the protein concentration in these ascites or the levels of serum CA125, a tumor antigen which is used in the clinic as a marker of tumor burden. The effect of ascites on cisplatin- and paclitaxel-induced cell death was assessed with 4 ascites having inhibitory effect on TRAIL-induced cell death and 2 that do not. The four ascites with prosurvival activity against TRAIL had some inhibitory on cisplatin and/or paclitaxel. Two ovarian cancer ascites, OVC346 and OVC509, also inhibited TRAIL cytotoxicity in 9 primary cultures of ovarian tumor and induced Akt activation in three of these primary cultures. Among a cohort of 35 patients with ascites, a threshold of TRAIL IC50 with ascites/IC50 without ascites > 2 was associated with shorter Disease-Free Interval. The prosurvival activity of ascites against TRAIL is associated with shorter Disease-Free Interval, which may be explained, at least in part, by ascites-induced cisplatin/paclitaxel resistance. Our findings suggest that ascites may contain prosurvival factors that protect against TRAIL and chemotherapy and consequently affect Disease progression.
G L Taddei - One of the best experts on this subject based on the ideXlab platform.
-
tumour infiltrating gamma delta t lymphocytes are correlated with a brief Disease Free Interval in advanced ovarian serous carcinoma
Annals of Oncology, 2005Co-Authors: Maria Rosaria Raspollini, Francesca Castiglione, Gianni Amunni, A. Villanucci, Francesca Garbini, Gianna Baroni, Rossi D Deglinnocenti, G L TaddeiAbstract:Abstract Background Significant progress has been made in understanding the molecular biology of ovarian carcinoma. Along with the molecular characteristics of cancer, the patient's response to the tumour may also contribute to survival; in particular, the effect of the immune system may play an important role on survival of cancer patients. Patients and methods We analysed the CD3 positive tumour-infiltrating T cells and direct molecular assessment of T cell receptors (TCRs) gamma and beta in 95 advanced ovarian carcinomas. Results Gamma/delta T cells are statistically correlated with a brief Disease-Free Interval (P = 0.036). CD3 positive tumour-infiltrating T cells are correlated with a brief Disease-Free Interval and with survival (P = 0.004 and P = 0.0001, respectively). CD3 positive tumour-infiltrating T cells are associated with clinical responsiveness to chemotherapy (P = 0.003). Conclusions Further studies are required to better understand the role of gamma/delta T cells in ovarian carcinoma, yet these data underline the importance of host immune response to cancer and the need to better study immune mechanisms to modulate the therapeutic treatment of cancer.
Jonathan M. Hernandez - One of the best experts on this subject based on the ideXlab platform.
-
stage and Disease Free Interval help select patients for surgical management of locally recurrent and metastatic adrenocortical carcinoma
Journal of Surgical Oncology, 2020Co-Authors: Reed I. Ayabe, Christine M. Kariya, Meghan L. Good, Seth M. Steinberg, Jeremy L. Davis, Robert T. Ripley, Jonathan M. HernandezAbstract:BACKGROUND AND OBJECTIVES Chemotherapeutic options for patients with recurrent/metastatic adrenocortical carcinoma (ACC) are limited, leading to consideration for surgical management. We sought to determine characteristics associated with an unequivocal survival benefit amongst patients undergoing re-resection or metastasectomy. METHODS Patients who underwent surgery for recurrent/metastatic ACC were identified and stratified into two groups: those with postoperative survival comparable with what has been reported with chemotherapy alone ( 24 months). Those who survived between 12 and 24 months were excluded, as the objective was to characterize patients who most distinctly benefited from resection. Clinicopathologic and treatment variables were evaluated for associations with survival. RESULTS Forty-three patients survived more than 24 months and 15 patients died less than 12 months after reoperation. Tumor stage (odds ratio [OR], 0.66; 95% confidence Interval [CI], 0.45-0.96) and Disease-Free Interval (DFI; OR, 3.23; 95% CI, 1.68-6.22) were associated with prolonged survival. Tumor size, hormonal status, resection margin, and treatment with chemotherapy, radiation, and mitotane were not associated with prolonged survival. Patients who survived more than 24 months underwent more procedures for subsequent recurrences (median 4 vs 2; P < .001). CONCLUSION Stage and DFI can help select optimal candidates for resection of recurrent/metastatic ACC. Patients selected for surgical management should be informed of the likelihood of requiring multiple interventions.
-
Stage and Disease‐Free Interval help select patients for surgical management of locally recurrent and metastatic adrenocortical carcinoma
Journal of surgical oncology, 2019Co-Authors: Reed I. Ayabe, Christine M. Kariya, Meghan L. Good, Seth M. Steinberg, Jeremy L. Davis, Robert T. Ripley, Jonathan M. HernandezAbstract:BACKGROUND AND OBJECTIVES Chemotherapeutic options for patients with recurrent/metastatic adrenocortical carcinoma (ACC) are limited, leading to consideration for surgical management. We sought to determine characteristics associated with an unequivocal survival benefit amongst patients undergoing re-resection or metastasectomy. METHODS Patients who underwent surgery for recurrent/metastatic ACC were identified and stratified into two groups: those with postoperative survival comparable with what has been reported with chemotherapy alone ( 24 months). Those who survived between 12 and 24 months were excluded, as the objective was to characterize patients who most distinctly benefited from resection. Clinicopathologic and treatment variables were evaluated for associations with survival. RESULTS Forty-three patients survived more than 24 months and 15 patients died less than 12 months after reoperation. Tumor stage (odds ratio [OR], 0.66; 95% confidence Interval [CI], 0.45-0.96) and Disease-Free Interval (DFI; OR, 3.23; 95% CI, 1.68-6.22) were associated with prolonged survival. Tumor size, hormonal status, resection margin, and treatment with chemotherapy, radiation, and mitotane were not associated with prolonged survival. Patients who survived more than 24 months underwent more procedures for subsequent recurrences (median 4 vs 2; P
Rahul A.k. Samlal - One of the best experts on this subject based on the ideXlab platform.
-
Disease Free Interval and recurrence pattern after the okabayashi variant of wertheim s radical hysterectomy for stage ib and iia cervical carcinoma
International Journal of Gynecological Cancer, 1996Co-Authors: Rahul A.k. Samlal, Jacobus Van Der Velden, B.w. Ketting, A. A. M. Hart, Gonzalez D Gonzalez, F Ten J W Kate, F. B. LammesAbstract:From January 1982 to December 1991 271 patients underwent radical hysterectomy according to the Okabayashi modification for cervical carcinoma stage IB and IIA. Intraoperative complications occurred in 3.3%. The urinary fistula rate was only 2.2%. The 5-year Disease-Free Interval (DFI) was 90%. In a univariate analysis tumor size 3 cm (n = 99), positive pelvic nodes (n = 53), adenocarcinoma (n = 58) and parametrial involvement (n = 36) were all associated with a significantly decreased DFI. Recurrence occurred in 27 patients (10%) of whom 22 died of Disease. In adenocarcinoma, DFI was poor when positive pelvic nodes were present. In squamous cell carcinoma however, DFI was not influenced by pelvic node status. In patients with squamous cell carcinoma the locoregional recurrence rate was 3.4% when pelvic nodes were negative, whereas in those with positive nodes it was 5.8%. These data show that the Okabayashi modification of Wertheim’s radical hysterectomy is a safe procedure resulting in very good locoregional tumor control, especially in patients with squamous cell cancer of the cervix.
-
Disease‐Free Interval and recurrence pattern after the Okabayashi variant of Wertheim’s radical hysterectomy for stage IB and IIA cervical carcinoma
International Journal of Gynecological Cancer, 1996Co-Authors: Rahul A.k. Samlal, Jacobus Van Der Velden, B.w. Ketting, D. González González, F.j.w. Ten Kate, A. A. M. Hart, F. B. LammesAbstract:From January 1982 to December 1991 271 patients underwent radical hysterectomy according to the Okabayashi modification for cervical carcinoma stage IB and IIA. Intraoperative complications occurred in 3.3%. The urinary fistula rate was only 2.2%. The 5-year Disease-Free Interval (DFI) was 90%. In a univariate analysis tumor size 3 cm (n = 99), positive pelvic nodes (n = 53), adenocarcinoma (n = 58) and parametrial involvement (n = 36) were all associated with a significantly decreased DFI. Recurrence occurred in 27 patients (10%) of whom 22 died of Disease. In adenocarcinoma, DFI was poor when positive pelvic nodes were present. In squamous cell carcinoma however, DFI was not influenced by pelvic node status. In patients with squamous cell carcinoma the locoregional recurrence rate was 3.4% when pelvic nodes were negative, whereas in those with positive nodes it was 5.8%. These data show that the Okabayashi modification of Wertheim’s radical hysterectomy is a safe procedure resulting in very good locoregional tumor control, especially in patients with squamous cell cancer of the cervix.